Nanoparticle-Delivered 2-PAM for Rat Brain Protection against Paraoxon Central Toxicity

ACS Appl Mater Interfaces. 2017 May 24;9(20):16922-16932. doi: 10.1021/acsami.7b04163. Epub 2017 May 15.

Abstract

Solid lipid nanoparticles (SLNs) are among the most promising nanocarriers to target the blood-brain barrier (BBB) for drug delivery to the central nervous system (CNS). Encapsulation of the acetylcholinesterase reactivator, pralidoxime chloride (2-PAM), in SLNs appears to be a suitable strategy for protection against poisoning by organophosphorus agents (OPs) and postexposure treatment. 2-PAM-loaded SLNs were developed for brain targeting and delivery via intravenous (iv) administration. 2-PAM-SLNs displayed a high 2-PAM encapsulation efficiency (∼90%) and loading capacity (maximum 30.8 ± 1%). Drug-loaded particles had a mean hydrodynamic diameter close to 100 nm and high negative zeta potential (-54 to -15 mV). These properties contribute to improve long-term stability of 2-PAM-SLNs when stored both at room temperature (22 °C) and at 4 °C, as well as to longer circulation time in the bloodstream compared to free 2-PAM. Paraoxon-poisoned rats (2 × LD50) were treated with 2-PAM-loaded SLNs at a dose of 2-PAM of 5 mg/kg. 2-PAM-SLNs reactivated 15% of brain AChE activity. Our results confirm the potential use of SLNs loaded with positively charged oximes as a medical countermeasure both for protection against OPs poisoning and for postexposure treatment.

Keywords: acetylcholinesterase; blood−brain barrier; drug delivery systems; organophosphorus agent; paraoxon; pralidoxime chloride; solid lipid nanoparticles.

MeSH terms

  • Animals
  • Brain
  • Cholinesterase Reactivators
  • Lipids
  • Nanoparticles*
  • Paraoxon
  • Pralidoxime Compounds
  • Rats

Substances

  • Cholinesterase Reactivators
  • Lipids
  • Pralidoxime Compounds
  • pralidoxime
  • Paraoxon